FDA

What Does It Mean That Oracle is Partnering with the Trump Administration to Study Unproven COVID-19 Drugs?

Cross-posted from Written Description, where it originally appeared on March 30, 2020.  By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob Sherkow One of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. We decided to unpack this story for ourselves and then…

pills

Published:

Cross-posted from Written Description, where it originally appeared on March 30, 2020. 

By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob Sherkow

One of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. We decided to unpack this story for ourselves and then to collectively share our thoughts in a short explainer.

Click here to read the full post at Written Description.

 

About the authors

  • Lisa Larrimore Ouellette

    Lisa Larrimore Ouellette is the Deane F. Johnson Professor of Law at Stanford Law School and a Senior Fellow at the Stanford Institute for Economic Policy Research.

    More from Lisa

  • W. Nicholson Price II

    W. Nicholson Price II was an Academic Fellow at the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School.

    More from Nicholson

  • Rachel Sachs

    Rachel Sachs is Professor of Law at Washington University, and was a 2014-2016 Petrie-Flom Center Academic Fellow.

    More from Rachel

  • Jacob S. Sherkow

    Jacob Sherkow is a law professor at the University of Illinois Urbana-Champagne, and was a 2019-2020 Edmond J. Safra/Petrie-Flom Center Joint Fellow-in-Residence.

    More from Jacob